Platelet FcγRIIA Receptor Surface Expression Is Increased in Patients With ESRD and Is Associated With Atherosclerotic Cardiovascular Events

American Journal of Kidney Diseases

Volumn 49, Issue 1, 2007, Pages 127-134

  El Shahawy, Mohamed ^a   Noureddin, Mazen ^a   Abdullah, Hesham ^a   Mack, Wendy J ^a   Calverley, David C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

atherosclerosis; cardiovascular disease; end stage renal disease (ESRD); Kidney failure; myocardial ischemia; platelet Fc receptor; uremia

Indexed keywords

FC RECEPTOR; HEMOGLOBIN; IMMUNOGLOBULIN G; FC GAMMA RECEPTOR IIA; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FLUORESCENCE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SAMPLE SIZE; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE; UNITED STATES; UREMIA; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; METABOLISM; MIDDLE AGED;

ADULT; ANTIGENS, CD; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, IGG;

EID: 33845570472     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.09.022     Document Type: Article

References (28)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
2. US Renal Data System: 1999 USRDS Annual Data Report (1999), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
3. Becker B.N., Himmelfarb J., Henrich W.L., and Hakim R.M. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8 (1997) 475-486
4. Sarnak M.J., Coronado B.E., Greene T., et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57 (2002) 327-335
5. Zoccali C., Mallamaci F., and Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 85 (2003) S105-S110
6. Bombeli T., Schwartz B.R., and Harlan J.M. Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), vß3 integrin, and GPIb. J Exp Med 187 (1998) 329-339
7. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 340 (1999) 115-126
8. Davies M.J., and Thomas T. The pathological basis and microanatomy of occlusive thrombus formation in human coronary arteries. Philos Trans R Soc Lond (Biol) 294 (1981) 225-229
9. Colwell J.A., Winocour P.D., and Lopes-Virella M.F. Platelet function and platelet-plasma interactions in atherosclerosis and diabetes mellitus. In: Rifkin H., and Porte D. (Eds). Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice (1990), Elsevier Science, Amsterdam, The Netherlands 249-256
10. Calverley D.C., Brass E., Hacker M.R., et al. Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 164 (2002) 261-267
11. Hodis H.N., Mack W.J., LaBree L., et al. Alpha-tocopherol supplementation in healthy individuals reduces LDL oxidation but not atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106 (2002) 1453-1459
12. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996) 53-61
13. Vlagopoulos P.T., Tighiouart H., Weiner D.E., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J Am Soc Nephrol 16 (2005) 3403-3410
14. Anand I.S., Chandrashekhar Y., Ferrari R., Poole-Wilson P.A., and Harris P.C. Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70 (1993) 357-362
15. Elhendy A., Modesto K.M., Mahoney D.W., Khandheria B.K., Seward J.B., and Pellikka P.A. Prediction of mortality in patients with left ventricular hypertrophy by clinical, exercise stress, and echocardiographic data. J Am Coll Cardiol 41 (2003) 129-135
16. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
17. Jurkovitz C.T., Abramson J.L., Vaccarino L.V., Weintraub W.S., and McClellan W.M. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 14 (2003) 2919-2925
18. Cassel D.L., Keller M.A., Surrey S., et al. Differential expression of FcγRIIA, FcγRIIB, and FcγRIIC in hematopoietic cells: Analysis of transcripts. Mol Immunol 30 (1993) 451-460
19. Warkentin T.E., and Kelton J.G. Heparin-induced thrombocytopenia. Prog Hemost Thromb 10 (1991) 1-34
20. Chong B.H., Pilgrim R.L., Cooley M.A., and Chesterman C.N. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 81 (1993) 988-993
21. Rosenfeld S.I., Ryan D.H., Looney R.J., Anderson C.L., Abraham G.N., and Leddy J.P. Human Fc receptors: Stable inter-donor variation in quantitative expression on platelets correlates with functional responses. J Immunol 138 (1987) 2869-2873
22. Tomiyama Y., Kunicki T.J., Zipf T.F., Ford S.B., and Aster R.H. Response of human platelets to activating monoclonal antibodies: Importance of FcRII (CD32) phenotype and level of expression. Blood 80 (1992) 2261-2268
23. Morrow D.A., and Braunwald E. Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation 108 (2003) 250-252
24. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
25. Jilma B., Joukhadar C., Derhaschnig U., et al. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clin Sci (Lond) 104 (2003) 189-193
26. Ebihara I., Nakamura T., Shimada N., and Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32 (1998) 544-550
27. Cayley Jr. W.E., Asselbergs F.W., Cohen-Tervaert J.W., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 350 (2004) 516-518
28. Stuveling E.M., Bakker S.J.L., Hillege H.L., de Jong P.E., Gans R.O.B., and de Zeeuw D. Biochemical risk markers: A novel area for better prediction of renal risk?. Nephrol Dial Transplant 20 (2005) 497-508